Терапия остеоартрита коленных суставов с точки зрения доказательной медицины: ожидаемые краткосрочные, среднесрочные и долгосрочные результаты применения рецептурного кристаллического глюкозамина сульфата

Потребность в эффективных препаратах для терапии остеоартрита (ОА) коленных суставов (КС) постоянно растает. В современных руководствах рекомендуется применять при этом заболевании симптоматические средства замедленного действия (SYSADOA), такие как глюкозамин (ГКА). Среди различных лекарственных средств, содержащих ГКА, высокая биодоступность и клиническая эффективность доказаны только для рецептурного кристаллического ГКА сульфата (рГКАС). В нескольких метаанализах и сетевых метаанализах было показано, что рГКАС в дозе 1500 мг 1 раз в сутки превосходит по эффективности другие продукты на основе ГКА (такие как ГКА гидрохлорид с натрия сульфатом или без него) и комбинации ГКА с хондроитина сульфатом (ХС) с точки зрения снижения интенсивности боли и улучшения функционального состояния. В этих исследованиях был подтвержден благоприятный профиль безопасности рГКАС, который по частоте развития нежелательных явлений был сопоставим с плацебо. Фармакоэкономические исследования также продемонстрировали большую экономическую эффективность рГКАС по сравнению с другими лекарственными средствами ГКА.
Группа российских экспертов на совещании консультативного комитета рассмотрела свидетельства в пользу применения рГКАС и доказательства его эффективности при лечении ОА КС в сравнении с другими продуктами, в состав которых входит ГКА, и фиксированной комбинации ГКА с ХС. С учетом полученных результатов использование рГКАС в дозе 1500 мг 1 раз в сутки рекомендовано в качестве рационального выбора для лечения ОА КС.

1. Centers for Disease Control and Prevention. What is osteoarthritis (OA)? https://www.cdc.gov/arthritis/basics/osteoarthritis.htm.

2. Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016 Dec;59(5-6):333-9. doi: 10.1016/j.rehab.2016.07.004. Epub 2016 Aug 18.

3. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19.

4. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.

5. Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018 Feb; 30(2):111-7. doi: 10.1007/s40520-017-0861-1. Epub 2017 Nov 24.

6. Saengnipanthkul S, Waikakul S, Rojanasthien S, et al. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. Int J Rheum Dis. 2019 Mar; 22(3):376-85. doi: 10.1111/1756-185X.13068. Epub 2017 Mar 23.

7. Kucharz EJ, Kovalenko V, Szanto S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016 Jun;32(6):997-1004. doi: 10.1185/03007995.2016.1154521. Epub 2016 Feb 26.

8. Bruyere O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7. doi: 10.1016/j.semarthrit.2015.11.011. Epub 2015 Dec 2.

9. Reginster JY, Cooper C, Hochberg M, et al. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin. 2015 May;31(5):1041-5. doi: 10.1185/03007995.2015.1027183. Epub 2015 Mar 24.

10. Herrero-Beaumont G, Rovati L. Use of crystalline glucosamine sulfate in osteoarthritis. Future Rheumatology. 2006;(1):397-414.

11. Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно-практическая ревматология. 2015;53(1):63-8.

12. Lila AM, Denisov LN, Zotkin EG, et al. Pharmacological Management of Osteoarthritis with a Focus on Symptomatic Slow-Acting Drugs: Recommendations from Leading Russian Experts. J Clin Rheumatol. 2021 Dec 1; 27(8):e533-e539. doi: 10.1097/RHU.0000000000001507.

13. Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a metaanalysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014 Dec;66(12): 1844-55. doi: 10.1002/acr.22376.

14. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002946. doi: 10.1002/14651858.CD002946.pub2.

15. Beaudart C, Lengele L, Leclercq V, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020 Dec;80(18):1947-59. doi: 10.1007/s40265-020-01423-8.

16. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018 Dec 25;320(24): 2564-79. doi: 10.1001/jama.2018.19319.

17. Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020 Dec 26;12:1759720X20975927. doi: 10.1177/1759720X20975927. eCollection 2020.

18. Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). Jan-Mar 2017;15(1):943. doi: 10.18549/PharmPract.2017.01.943. Epub 2017 Mar 15.

19. Gnylorybov AM, Ter-Vartanian SK, Golovach IY, et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020 Aug 4;13: 1179544120946743. doi: 10.1177/11795 44120946743. eCollection 2020.

20. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012 Jun;4(3):167-80. doi: 10.1177/1759720X12437753.

21. Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017 Apr 12;6(1):79. doi: 10.1186/s13643-017-0473-z.

22. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. (Supplementary content). JAMA. 2018 Dec 25;320(24):2564-79. doi: 10.1001/jama.2018.19319.

23. Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage. 2010 Mar;18(3):297-302. doi: 10.1016/j.joca.2009.10.013. Epub 2009 Nov 10.

24. Tenti S, Giordano N, Mondanelli N, et al. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020 Jun;32(6):1161-72. doi: 10.1007/s40520-019-01305-4. Epub 2019 Aug 19.

25. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650): 924-6. doi: 10.1136/bmj.39489.470347.AD.

26. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

27. Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet. 2017 Jul 8;390(10090):e21-e33. doi: 10.1016/S0140-6736(17)31744-0.

28. Gang D, Xiaguang C, Kanghua Y, et al. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Tropical Journal of Pharmaceutical Research. 2019;18(2):397-402.

29. Cheleschi S, Tenti S, Giannotti S, et al. A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflamatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes. Int J Mol Sci. 2021 Aug 20;22(16):8980. doi: 10.3390/ijms22168980.

30. Sun Y, Wang C, Gong C. Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis. J Orthop Surg Res. 2020 Apr 16;15(1):150. doi: 10.1186/s13018-020-01648-z.

31. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251-6. doi: 10.1016/S0140-6736(00)03610-2.

32. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007 Feb;56(2):555-67. doi: 10.1002/art.22371.

33. Makhous R. Effectiveness and Safety of Glucosamine in the Treatment of Osteoarthritis. Research Journal of Pharmacy and Technology. 2018;11:489.

34. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002 Oct 14;162(18): 2113-23. doi: 10.1001/archinte.162.18.2113.

35. Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi: 10.1007/s40266-019-00662-z.

36. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011 Jan;27(1):14-27. doi: 10.1002/dmrr.1150. Epub 2010 Dec 7.

37. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A DoubleBlind, Placebo-Controlled Clinical Trial. Arch Rheumatol. 2016 Oct 1;31(4):340-5. doi: 10.5606/ArchRheumatol.2016.5632. eCollection 2016 Dec.

38. Veronese N, Cooper C, Reginster JY, et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum. 2019 Aug;49(1):9-19. doi: 10.1016/j.semarthrit.2019.01.005. Epub 2019 Jan 11.

39. Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung. 1998 May; 48(5):469-74.

40. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007s40266-019-00660-1.

41. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

42. Gunter BR, Butler KA, Wallace RL, et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a metaanalysis. J Clin Pharm Ther. 2017 Feb;42(1): 27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26.

43. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006 Mar;99(3):132-40. doi: 10.1258/jrsm.99.3.132.

44. Al-Rashed F, Calay D, Lang M, et al. Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Sci Rep. 2018 Apr 19;8(1):6271. doi: 10.1038/s41598-018-24548-z.

45. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

46. Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S34-41. doi: 10.1016/j.semarthrit.2015.10.009. Epub 2015 Oct 29.

47. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebocontrolled trials. Osteoarthritis Cartilage. 2008 Feb;16(2):254-60. doi: 10.1016/j.joca.2007.06.011. Epub 2007 Jul 27.

48. Scholtissen S, Bruyere O, Neuprez A, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract. 2010 May;64(6):756-62. doi: 10.1111/j.1742-1241.2010.02362.x.

49. Developing NICE guidelines: the manual. Process and methods. National Institute for Health and Care Excellence; 2014. https://www.nice.org.uk/process/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869

50. Bruyere O, Reginster JY, Honvo G, Detilleux J. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res. 2019 Jun;31(6):881-7. doi: 10.1007/s40520-019-01138-1. Epub 2019 Feb 12.